These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 7997130

  • 1. [Enzyme replacement therapy in type 1 Gaucher's disease].
    Aggio MC, Fernández V, Marcilese M.
    Medicina (B Aires); 1994; 54(2):140-4. PubMed ID: 7997130
    [Abstract] [Full Text] [Related]

  • 2. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE.
    N Engl J Med; 1991 May 23; 324(21):1464-70. PubMed ID: 2023606
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 23; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 4. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 5. [Gaucher's disease: pathogenesis, diagnosis and therapy].
    Pregun I, Tulassay Z.
    Orv Hetil; 2004 Sep 12; 145(37):1883-90. PubMed ID: 15493618
    [Abstract] [Full Text] [Related]

  • 6. [Response criteria for enzyme substitution in Gaucher disease].
    Berthold F, Sieverts H, Benz-Bohm G, Landwehr P, Harzer K.
    Monatsschr Kinderheilkd; 1992 Oct 12; 140(10):740-4. PubMed ID: 1331780
    [Abstract] [Full Text] [Related]

  • 7. [Gaucher disease: diagnosis and treatment].
    Fumić K, Stavljenić-Rukavina A, Mrsić M, Potocki K.
    Acta Med Croatica; 2004 Oct 12; 58(5):353-8. PubMed ID: 15756799
    [Abstract] [Full Text] [Related]

  • 8. [Diagnosis and therapy of Gaucher disease].
    Ehlen C, Heintges T, Niederau C.
    Med Klin (Munich); 1995 May 15; 90(5):284-90. PubMed ID: 7791695
    [Abstract] [Full Text] [Related]

  • 9. [Update on Gaucher's disease].
    Virgolini L, Silvestri F, Baccarani M.
    Minerva Med; 1993 Mar 15; 84(3):81-7. PubMed ID: 8492969
    [Abstract] [Full Text] [Related]

  • 10. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
    Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW.
    Ann Neurol; 1997 Oct 15; 42(4):613-21. PubMed ID: 9382473
    [Abstract] [Full Text] [Related]

  • 11. [Gaucher's disease ].
    Belmatoug N, Caubel I, Stirnemann J, Billette de Villemeur T.
    J Soc Biol; 2002 Oct 15; 196(2):141-9. PubMed ID: 12360743
    [Abstract] [Full Text] [Related]

  • 12. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
    Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D.
    Plant Biotechnol J; 2007 Sep 15; 5(5):579-90. PubMed ID: 17524049
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow transplantation in Gaucher's disease: effect of mixed chimeric state.
    Chan KW, Wong LT, Applegarth D, Davidson AG.
    Bone Marrow Transplant; 1994 Aug 15; 14(2):327-30. PubMed ID: 7994251
    [Abstract] [Full Text] [Related]

  • 14. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
    Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE.
    Blood Cells Mol Dis; 2010 Mar 15; 44(3):181-7. PubMed ID: 20074983
    [Abstract] [Full Text] [Related]

  • 15. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002 Mar 15; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 16. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
    McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, Hutto E, Grabowski GA, Cheng SH, Marshall J.
    J Gene Med; 2006 Jun 15; 8(6):719-29. PubMed ID: 16528760
    [Abstract] [Full Text] [Related]

  • 17. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ.
    FEBS J; 2006 Sep 15; 273(17):4082-92. PubMed ID: 16934036
    [Abstract] [Full Text] [Related]

  • 18. Studies on the turnover of exogenous mannose-terminal glucocerebrosidase in rat liver lysosomes.
    Murray GJ, Oliver KL, Jin FS, Brady RO.
    J Cell Biochem; 1995 Feb 15; 57(2):208-17. PubMed ID: 7759558
    [Abstract] [Full Text] [Related]

  • 19. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S, Roberts A, Patterson MA, Amato D.
    Blood Cells Mol Dis; 2009 Feb 15; 43(3):289-93. PubMed ID: 19793665
    [Abstract] [Full Text] [Related]

  • 20. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 15; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.